Condition: Acute Myeloid Leukemia, in Relapse · Acute Myeloid Leukemia Refractory · MDS (Myelodysplastic Syndrome) · Sponsor: ARCE Therapeutics, Inc.
This is a phase I/2, interventional, open-label, multicenter study to assess the safety and efficacy of ARD103 in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome.
This description comes directly from the study's public registry record.
ARCE Therapeutics, Inc · +886-2-26581868 · contact@arcetherapeutics.com
Always discuss trial participation with your own doctor first.
| Novant Health Cancer Institute | Charlotte, North Carolina, United States | Recruiting |
| Novant Health Cancer Institute | Winston-Salem, North Carolina, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06680752